DOXURAL 150MG PROLONGED RELEASE CAPSULES

البلد: قبرص

اللغة: اليونانية

المصدر: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

العنصر النشط:

VENLAFAXINE HYDROCHLORIDE

متاح من:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

ATC رمز:

N06AX16

INN (الاسم الدولي):

VENLAFAXINE

جرعة:

150MG

الشكل الصيدلاني:

PROLONGED RELEASE CAPSULES

تركيب:

VENLAFAXINE HYDROCHLORIDE (8000001467) 169.74MG

طريقة التعاطي:

ORAL USE

نوع الوصفة الطبية :

Εθνική Διαδικασία

المجال العلاجي:

VENLAFAXINE

ملخص المنتج:

Νομικό καθεστώς: Με Ιατρική Συνταγή; PACK WITH 7 CAPS IN BLISTER(S) (310001001) 7 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 10 CAPS IN BLISTER(S) (310001002) 10 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 14 CAPS IN BLISTER(S) (310001003) 14 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 20 CAPS IN BLISTER(S) (310001004) 20 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 28 CAPS IN BLISTER(S) (310001005) 28 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 30 CAPS IN BLISTER(S) (310001006) 30 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 50 CAPS IN BLISTER(S) (310001007) 50 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 98 CAPS IN BLISTER(S) (310001008) 98 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 100 CAPS IN BLISTER(S) (310001009) 100 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; BOTTLE WITH 50 CAPS (310001010) 50 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή; BOTTLE WITH 100 CAPS (310001011) 100 CAPSULE - Εγκεκριμένο - Με Ιατρική Συνταγή

خصائص المنتج

1.
NAME OF THE MEDICINAL PRODUCT
Doxural 37,5
Venlafaxine 37,5 mg Prolonged-release capsules.
Doxural 75
Venlafaxine 75 mg Prolonged-release capsules.
Doxural 150
Venlafaxine 150 mg Prolonged-release capsules.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
For 37,5 mg strength:
Each prolonged-release capsule contains venlafaxine hydrochloride
equivalent to 37,5 mg
venlafaxine.
For 75 mg strength:
Each prolonged-release capsule contains venlafaxine hydrochloride
equivalent to 75 mg venlafaxine.
For 150 mg strength:
Each prolonged-release capsule contains venlafaxine hydrochloride
equivalent to 150 mg venlafaxine.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
_Doxural 37,5 _
_ _
_ mg prolonged-release capsules _
_ _
_ _
White to off-white pellets filled in hard gelatin capsule shells size
“3” with orange cap and clear
transparent body.
_Doxural 75 _
_ _
_ mg prolonged-release capsules_
_ _
_ _
1
SUMMARY OF PRODUCT CHARACTERISTICS
White to off-white pellets filled in hard gelatin capsule shells size
“1” with yellow cap and clear
transparent body.
_Doxural 150 _
_ _
_ mg prolonged-release capsules _
_ _
_ _
White to off-white pellets filled in hard gelatin capsule shells size
“0” with buff cap and clear
transparent body.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of major depressive episodes.
For prevention of recurrence of major depressive episodes.
Treatment of social anxiety disorder.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Major depressive episodes
The recommended starting dose for prolonged-release venlafaxine is 75
mg given once daily. Patients
not responding to the initial 75 mg/day dose may benefit from dose
increases up to a maximum dose
of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or
more. If clinically warranted
due to symptom severity, dose increases can be made at more frequent
intervals, but not less than 4
days.
Because of the risk of dose-related adverse effects, dose increments
should be made only after a
clinical evaluatio